Innovator IBD Breakout Opportunities ETF (NYSEARCA:BOUT) Short Interest Up 700.0% in September

Innovator IBD Breakout Opportunities ETF (NYSEARCA:BOUT) saw a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 800 shares, a growth of 700.0% from the August 31st total of 100 shares. Based on an average trading volume of 1,300 shares, the short-interest ratio is currently 0.6 days. Based on an average trading volume of 1,300 shares, the short-interest ratio is currently 0.6 days.

Innovator IBD Breakout Opportunities ETF Stock Performance

NYSEARCA:BOUT opened at $39.11 on Friday. The company has a fifty day moving average of $38.02 and a two-hundred day moving average of $36.16. The stock has a market capitalization of $11.73 million, a PE ratio of 28.69 and a beta of 0.98. Innovator IBD Breakout Opportunities ETF has a fifty-two week low of $31.08 and a fifty-two week high of $42.41.

Hedge Funds Weigh In On Innovator IBD Breakout Opportunities ETF

An institutional investor recently raised its position in Innovator IBD Breakout Opportunities ETF stock. Osaic Holdings Inc. boosted its stake in shares of Innovator IBD Breakout Opportunities ETF (NYSEARCA:BOUT) by 39.7% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 2,102 shares of the company’s stock after acquiring an additional 597 shares during the period. Osaic Holdings Inc. owned about 0.70% of Innovator IBD Breakout Opportunities ETF worth $77,000 at the end of the most recent quarter.

Innovator IBD Breakout Opportunities ETF Company Profile

The Innovator IBD Breakout Opportunities ETF (BOUT) is an exchange-traded fund that is based on the IBD Breakout Stocks Total Return index. The fund tracks an index of US-listed stocks that are likely to breakout, as determined by technical analysis. Holdings are weighted by a mix of fundamental and technical factors BOUT was launched on Sep 13, 2018 and is managed by Innovator.